Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer

被引：0
作者：
Seruga, B. [1 ]
Gan, H. K. [1 ]
Knox, J. J. [1 ]
机构：
[1] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Div Hematol & Med Oncol, Toronto, ON, Canada
来源：
CURRENT ONCOLOGY | 2009年 / 16卷
关键词：
Sunitinib; sorafenib; temsirolimus; toxicity; side effects; management; RENAL-CELL CARCINOMA; TYROSINE KINASE INHIBITOR; CARDIAC-HYPERTROPHY; INTERFERON-ALPHA; DOUBLE-BLIND; SUNITINIB; HYPOTHYROIDISM; HYPERTENSION; MANAGEMENT; SAFETY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The toxicities of new, targeted drugs may diminish their effectiveness in advanced kidney cancer if those toxicities are not recognized and properly addressed early in patient treatment. Most of the drug-related toxicities in advanced kidney cancer are manageable with supportive care, obviating a need for long interruptions, dose reductions, or permanent discontinuation of the treatment.
引用
收藏
页码：S54 / S61
页数：8
相关论文
共 50 条
  • [31] Sorafenib tosylate in advanced kidney cancer: past, present and future
    Porta, Camillo
    Paglino, Chiara
    Imarisio, Ilaria
    Ferraris, Elisa
    ANTI-CANCER DRUGS, 2009, 20 (06) : 409 - 415
  • [32] Optimal Use of Targeted Agents for Advanced Gastrointestinal Stromal Tumours
    Reichardt, Peter
    ONCOLOGY, 2010, 78 (02) : 130 - 140
  • [33] Understanding, recognizing, and managing toxicities of targeted anticancer therapies
    Dy, Grace K.
    Adjei, Alex A.
    CA-A CANCER JOURNAL FOR CLINICIANS, 2013, 63 (04) : 249 - 279
  • [34] Management of advanced prostate cancer - new drugs
    Ullen, Anders
    Shah, Carl-Henrik
    Kirkali, Ziya
    ACTA ONCOLOGICA, 2011, 50 : 137 - 140
  • [35] Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy
    Patel, Hiten D.
    Karam, Jose A.
    Allaf, Mohamad E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (36) : 3601 - +
  • [36] Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience
    De Gobbi, Alberto
    Biasoni, Davide
    Catanzaro, Mario
    Nicolai, Nicola
    Piva, Luigi
    Stagni, Silvia
    Torelli, Tullio
    Procopio, Giuseppe
    Verzoni, Elena
    Grassi, Paolo
    Colecchia, Maurizio
    Paolini, Biagio
    Spreafico, Carlo
    Marchiano, Alfonso
    Salvioni, Roberto
    TUMORI JOURNAL, 2018, 104 (05): : 388 - 393
  • [37] Risk Assessment of Drug Interaction Potential and Concomitant Dosing Pattern on Targeted Toxicities in Pediatric Cancer Patients
    Jeffrey S. Barrett
    Dimple Patel
    Erin Dombrowsky
    Gaurav Bajaj
    Jeffrey M. Skolnik
    The AAPS Journal, 2013, 15 : 775 - 786
  • [38] KIDNEY CANCER Bisphosphonates in the era of antiangiogenic targeted therapy
    Roos, Frederik C.
    NATURE REVIEWS UROLOGY, 2014, 11 (06) : 315 - 316
  • [39] Kidney Cancer Pathology in the New Context of Targeted Therapy
    Allory, Yves
    Culine, Stephane
    de la Taille, Alexandre
    PATHOBIOLOGY, 2011, 78 (02) : 90 - 98
  • [40] Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm
    Shuch, Brian
    Riggs, Stephen B.
    LaRochelle, Jeff C.
    Kabbinavar, Fairooz F.
    Avakian, Raffi
    Pantuck, Allan J.
    Patard, Jean-Jacques
    Belldegrun, Arie S.
    BJU INTERNATIONAL, 2008, 102 (06) : 692 - 696
12345